Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Sexually Transmitted Infections
|
January 22, 2016
Making every contact count: improving the assessment of gay, bisexual and other men who have sex with men using a structured proforma
Ming J Lee, Bhavna Oza, Mark Pakianathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2022
Reply to U. Capitanio et al
Bhavna Oza, Tim Eisen, Grant D Stewart, et al.
European Urology Open Science
|
August 4, 2025
Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials
Bhavna Oza, Eleni Frangou, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen, Eleni Frangou, Bhavna Oza, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting
Angela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
Nature Cancer
|
December 24, 2021
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study
Annika Fendler, Scott T C Shepherd, Lewis Au, et al.
Nature Cancer
|
February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Annika Fendler, Scott T C Shepherd, Lewis Au, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Sexually Transmitted Infections
|
January 22, 2016
Making every contact count: improving the assessment of gay, bisexual and other men who have sex with men using a structured proforma
Ming J Lee, Bhavna Oza, Mark Pakianathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2022
Reply to U. Capitanio et al
Bhavna Oza, Tim Eisen, Grant D Stewart, et al.
European Urology Open Science
|
August 4, 2025
Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials
Bhavna Oza, Eleni Frangou, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen, Eleni Frangou, Bhavna Oza, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting
Angela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
Nature Cancer
|
December 24, 2021
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study
Annika Fendler, Scott T C Shepherd, Lewis Au, et al.
Nature Cancer
|
February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Annika Fendler, Scott T C Shepherd, Lewis Au, et al.
Page
of 1